# [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients

> **NCT05222269** · PHASE2 · TERMINATED · sponsor: **Pentixapharm AG** · enrollment: 1 (actual)

## Conditions studied

- CNS Lymphoma

## Interventions

- **DRUG:** 68Ga-PTF

## Key facts

- **NCT ID:** NCT05222269
- **Lead sponsor:** Pentixapharm AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-05
- **Primary completion:** 2023-01-25
- **Final completion:** 2023-01-25
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The study was early terminated due to low patient recruitment in already activated sites and difficult approval process in some of the anticipated countries. Thus, recruitment of the planned patient numbers in a reasonable time cannot be expected.
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05222269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05222269, "[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05222269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*